TERN

TERN

USD

Terns Pharmaceuticals Inc. Common Stock

$17.430+1.930 (12.452%)

Prix en Temps Réel

Healthcare
Biotechnologie
États-Unis

Graphique des Prix

Loading Chart...

Métriques Clés

Métriques de Marché
Fondamentaux de l'Entreprise
Statistiques de Trading

Métriques de Marché

Ouverture

$15.500

Haut

$18.740

Bas

$15.500

Volume

4.37M

Fondamentaux de l'Entreprise

Capitalisation Boursière

1.5B

Industrie

Biotechnologie

Pays

United States

Statistiques de Trading

Volume Moyen

1.85M

Bourse

NMS

Devise

USD

Intervalle sur 52 Semaines

Bas $1.865Actuel $17.430Haut $18.74

Actualités Connexes

Analyst Upgrades

Truist Securities Reiterates Buy on Terns Pharma, Raises Price Target to $28

Truist Securities analyst Srikripa Devarakonda reiterates Terns Pharma with a Buy and raises the price target from $20 to $28.

Voir plus
Truist Securities Reiterates Buy on Terns Pharma, Raises Price Target to $28
Analyst Upgrades

BMO Capital Maintains Outperform on Terns Pharma, Raises Price Target to $22

BMO Capital analyst Etzer Darout maintains Terns Pharma with a Outperform and raises the price target from $15 to $22.

Voir plus
BMO Capital Maintains Outperform on Terns Pharma, Raises Price Target to $22
Analyst Upgrades

Barclays Maintains Overweight on Terns Pharma, Raises Price Target to $27

Barclays analyst Etzer Darout maintains Terns Pharma with a Overweight and raises the price target from $14 to $27.

Voir plus
Barclays Maintains Overweight on Terns Pharma, Raises Price Target to $27
Analyst Upgrades

HC Wainwright & Co. Upgrades Terns Pharma to Buy, Announces $20 Price Target

HC Wainwright & Co. analyst Andres Y. Maldonado upgrades Terns Pharma from Neutral to Buy and announces $20 price target.

Voir plus
HC Wainwright & Co. Upgrades Terns Pharma to Buy, Announces $20 Price Target
Analyst Upgrades

William Blair Upgrades Terns Pharma to Outperform

William Blair analyst Andy Hsieh upgrades Terns Pharma from Market Perform to Outperform.

Voir plus
William Blair Upgrades Terns Pharma to Outperform
Analyst Upgrades

Terns Pharmaceuticals' Leukemia Drug Seen As Potential Disruptor In CML Treatment Landscape, Analyst Upgrades

Terns Pharmaceuticals shares rise after TERN-701 shows a 75% response rate in the CML trial, and William Blair upgrades the stock to Outperform.

GlobeNewswire

Terns Announces Abstract with Positive Clinical Data for TERN-701 in Relapsed/Refractory CML Selected for Oral Presentation at 67th ASH Annual Meeting

Unprecedented Phase 1 CML efficacy data with 64% MMR achievement by 24 weeks in a refractory patient population Encouraging safety and tolerability profile at all doses evaluated Company to host investor update call on